Literature DB >> 35586430

2-Aminoquinazolines as LRRK2 Inhibitors for Treating Parkinson's Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35586430      PMCID： PMC9109514          DOI： 10.1021/acsmedchemlett.2c00155

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  LRRK2 and idiopathic Parkinson's disease.

Authors:  Emily M Rocha; Matthew T Keeney; Roberto Di Maio; Briana R De Miranda; J Timothy Greenamyre
Journal:  Trends Neurosci       Date:  2022-01-04       Impact factor: 13.837

Review 2.  Autophagy system as a potential therapeutic target for neurodegenerative diseases.

Authors:  Mengying Cui; Tamotsu Yoshimori; Shuhei Nakamura
Journal:  Neurochem Int       Date:  2022-02-15       Impact factor: 3.921

Review 3.  New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.

Authors:  Konstantin Senkevich; Uladzislau Rudakou; Ziv Gan-Or
Journal:  Neuropharmacology       Date:  2021-10-07       Impact factor: 5.250

Review 4.  Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.

Authors:  Chiao-Yin Lee; Elisa Menozzi; Kai-Yin Chau; Anthony H V Schapira
Journal:  J Neurochem       Date:  2021-10-16       Impact factor: 5.372

Review 5.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

Review 6.  LRRK2 recruitment, activity, and function in organelles.

Authors:  Luis Bonet-Ponce; Mark R Cookson
Journal:  FEBS J       Date:  2021-07-01       Impact factor: 5.622
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.